Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients
NCT04894123 · GERCOR - Multidisciplinary Oncology Cooperative Group · PHASE2 · terminated · last registry update 2023-09-18 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Recruitment failure” | Open Targets' class: insufficient enrollment | Registry record, GERCOR - Multidisciplinary Oncology Cooperative Group |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TYMP in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-20Also stopped (terminated): Institut de Recherches Internationales Servier, Futuximab/modotuximab + Trifluridine/Tipiracil (NCT05223673)
- 2024-05-21Results posted on the registry: Academic and Community Cancer Research United, Panitumumab + Regorafenib (NCT03992456)
- 2024-05-02Also stopped (terminated): Elevar Therapeutics, Rivoceranib + Trifluridine/Tipiracil (NCT04073615)
- 2024-04-09Results posted on the registry: Merck Sharp & Dohme LLC, pembrolizumab + lenvatinib (NCT04776148)
- 2024-04-02Phase 3 first posted: Biotech Pharmaceutical Co., Ltd., Nimotuzumab injection + Placebo (NCT06343116)
- 2024-03-05Results posted on the registry: Institut de Recherches Internationales Servier, Futuximab/modotuximab + Trifluridine/Tipiracil (NCT05223673)
- 2024-01-10Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-A1811 + TAS-102, Regorafenib , Fruquintinib (NCT06199973)
- 2023-12-26Results posted on the registry: Taiho Oncology, Inc., Trifluridine/Tipiracil + Bevacizumab (NCT04737187)
- 2023-11-03Results posted on the registry: Karyopharm Therapeutics Inc, Selinexor + Pembrolizumab (NCT04854434)
- 2023-11-03Also stopped (terminated): Karyopharm Therapeutics Inc, Selinexor + Pembrolizumab (NCT04854434)
- 2023-02-22Also stopped (terminated): Universitätsklinikum Hamburg-Eppendorf, Trifluridine/tipiracil chemoradiation + Capecitabine based chemoradiation (NCT04177602)
- 2022-12-29Results posted on the registry: Academic and Community Cancer Research United, Binimetinib + Palbociclib (NCT03981614)
- 2022-10-31Phase 3 first posted: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + regorafenib (NCT05600309)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision